NASDAQ:SYRS Syros Pharmaceuticals - SYRS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.32 +0.21 (+4.11%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$5.05▼$5.6750-Day Range$3.03▼$5.3252-Week Range$3.02▼$21.00Volume221,474 shsAverage Volume139,377 shsMarket Capitalization$107.62 millionP/E RatioN/ADividend YieldN/APrice Target$17.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Syros Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside542.9% Upside$34.20 Price TargetShort InterestHealthy3.65% of Float Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment1.07Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($9.19) to ($5.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.72 out of 5 starsMedical Sector74th out of 1,053 stocksPharmaceutical Preparations Industry24th out of 519 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.20, Syros Pharmaceuticals has a forecasted upside of 542.9% from its current price of $5.32.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.65% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 39.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 72.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.89. Previous Next 3.9 News and Social Media Coverage News SentimentSyros Pharmaceuticals has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Syros Pharmaceuticals this week, compared to 1 article on an average week.Search Interest7 people have searched for SYRS on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows8 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.79% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.77% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($9.19) to ($5.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syros Pharmaceuticals (NASDAQ:SYRS) StockSyros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.Read More Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRS Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comAnalysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $34.20January 26, 2023 | markets.businessinsider.comSyros Gets Fast Track Designation In U.S. For Tamibarotene For Myelodysplastic Syndrome TreatmentFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 26, 2023 | msn.comSyros stock rises as tamibarotene gets FDA fast track status for rare blood cancerJanuary 26, 2023 | finance.yahoo.comSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic SyndromeJanuary 24, 2023 | seekingalpha.comSYRS Syros Pharmaceuticals, Inc.January 9, 2023 | finance.yahoo.comSyros Announces Clinical Updates and 2023 Strategic PrioritiesJanuary 5, 2023 | markets.businessinsider.comAnalyst Expectations for Syros Pharmaceuticals's FutureFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 23, 2022 | msn.comSyros Pharmaceuticals's Return On Capital Employed OverviewDecember 16, 2022 | finance.yahoo.comOne Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider upped their stake by 212% in the previous yearDecember 12, 2022 | finance.yahoo.comSyros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDSDecember 10, 2022 | finance.yahoo.comSyros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 TrialDecember 5, 2022 | finance.yahoo.comSyros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10November 22, 2022 | finance.yahoo.comSyros to Participate at Piper Sandler 34th Annual Healthcare ConferenceNovember 14, 2022 | finance.yahoo.comSyros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue EstimatesNovember 14, 2022 | finance.yahoo.comSyros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateNovember 8, 2022 | nasdaq.comSyros Pharmaceuticals Stock (NASDAQ:SYRS): Worse than a Powerball Lottery Ticket?November 7, 2022 | finance.yahoo.comSyros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022November 3, 2022 | finance.yahoo.comSyros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual MeetingOctober 5, 2022 | msn.comLooking Into Syros Pharmaceuticals's Recent Short InterestSeptember 23, 2022 | finance.yahoo.comSyros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?September 20, 2022 | seekingalpha.comSyros Pharmaceuticals: A Major Vote Of Confidence From InsidersSeptember 19, 2022 | msn.comHow Is The Market Feeling About Syros Pharmaceuticals?September 16, 2022 | finance.yahoo.comSyros Announces Closing of Merger with Tyme Technologies and Concurrent Private PlacementSeptember 16, 2022 | finanznachrichten.deTYME Technologies, Inc.: Syros and Tyme Technologies Announce Stockholder Approval of MergerSeptember 14, 2022 | finance.yahoo.comSyros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer DrugSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRS Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees124Year FoundedN/APrice Target and Rating Average Stock Price Forecast$34.20 High Stock Price Forecast$100.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+233.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($16.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,560,000.00 Net Margins-485.12% Pretax Margin-485.12% Return on Equity-141.16% Return on Assets-58.31% Debt Debt-to-Equity Ratio0.31 Current Ratio6.57 Quick Ratio6.57 Sales & Book Value Annual Sales$23.49 million Price / Sales4.58 Cash FlowN/A Price / Cash FlowN/A Book Value$13.76 per share Price / Book0.39Miscellaneous Outstanding Shares20,230,000Free Float17,639,000Market Cap$107.62 million OptionableOptionable Beta1.56 Key ExecutivesNancy A. SimonianPresident, Chief Executive Officer & DirectorJason HaasChief Financial OfficerEric R. OlsonChief Scientific OfficerDavid A. RothChief Medical OfficerConley CheeChief Commercial OfficerKey CompetitorsVaccitechNASDAQ:VACCCapricor TherapeuticsNASDAQ:CAPRF-star TherapeuticsNASDAQ:FSTXViveon Health AcquisitionNYSE:VHAQDaré BioscienceNASDAQ:DAREView All CompetitorsInsiders & InstitutionsFlagship Pioneering Inc.Sold 1,944,646 shares on 11/15/2022Ownership: 15.775%BlackRock Inc.Sold 1,279,076 shares on 11/15/2022Ownership: 3.893%State Street CorpSold 178,688 shares on 11/15/2022Ownership: 0.526%Federated Hermes Inc.Sold 214,576 shares on 11/15/2022Ownership: 0.379%Pathstone Family Office LLCBought 21,913 shares on 11/15/2022Ownership: 0.348%View All Insider TransactionsView All Institutional Transactions SYRS Stock - Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks. What is Syros Pharmaceuticals' stock price forecast for 2023? 5 equities research analysts have issued 12 month price objectives for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $15.00 to $100.00. On average, they expect the company's share price to reach $34.20 in the next twelve months. This suggests a possible upside of 542.9% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts. How have SYRS shares performed in 2023? Syros Pharmaceuticals' stock was trading at $3.59 at the beginning of the year. Since then, SYRS stock has increased by 48.2% and is now trading at $5.32. View the best growth stocks for 2023 here. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 584,700 shares, a decrease of 39.4% from the December 31st total of 964,400 shares. Based on an average daily volume of 108,000 shares, the days-to-cover ratio is currently 5.4 days. Approximately 3.7% of the company's stock are sold short. View Syros Pharmaceuticals' Short Interest. When is Syros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. View our SYRS earnings forecast. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its earnings results on Monday, November, 14th. The company reported ($2.41) earnings per share for the quarter, topping the consensus estimate of ($3.91) by $1.50. The firm had revenue of $3.89 million for the quarter, compared to the consensus estimate of $4.97 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 141.16% and a negative net margin of 485.12%. When did Syros Pharmaceuticals' stock split? Syros Pharmaceuticals's stock reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric R Olson, Eric R Olson, Mark J Alles, Richard A Young, Srinivas Akkaraju and Timothy Tyson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $5.32. How much money does Syros Pharmaceuticals make? Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $107.62 million and generates $23.49 million in revenue each year. The company earns $-86,560,000.00 in net income (profit) each year or ($16.41) on an earnings per share basis. How many employees does Syros Pharmaceuticals have? The company employs 124 workers across the globe. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com. This page (NASDAQ:SYRS) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.